Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 576 participants.
Also called NCT01760291
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 576 participants
- Sponsor
- Registry
-
NCT01760291
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01760291. Allocation not applicable; no masking; primary purpose prevention. Start 2012-09 (registry gives no type); primary completion 2019-04 (actual). Results posted on 2021-11-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
- Acronym
- CAP2
- Condition
- Atrial Fibrillation
- Intervention (Device)
- WATCHMAN LAA Closure Technology
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct01760291- Content hash
6e066686d4d039bbe6b4da2f92c353009475271115671322a3e9449e32a9c0b8